NEW YORK, October 13, 2015 — MTS Health Investors, LLC (“MTS”), the New York-based healthcare private equity firm, announced today that it has successfully completed the sale of its portfolio company, DNA Diagnostics Center (“DDC” or the “Company”), to GHO Capital for $110 million.
DDC is a market leading diagnostics business and is one of the world’s largest providers of private DNA testing services. The Company’s platform technology offers a wide range of products in the fields of biological family relationship testing, veterinary services, forensic services and medical applications for the pharmaceutical industry including cell-line authentication. DDC currently processes over 750,000 tests per annum in its state-of-the-art facility and is consistently recognised as the laboratory of choice for high quality results and excellence in customer service.
DDC President and CEO, Peter Vitulli, said, “The exceptional support and commitment provided by MTS was instrumental to our success. Their partnership afforded us with the necessary resources to create a premier, global organization in the testing space that has become known for our best-in-class testing capabilities and reputation.”
“It has been exciting and rewarding to partner with the DDC management team as they have executed on their growth strategy over the past few years,” said MTS Managing Director Alex Buzik. “We are thankful for the opportunity to work with such high-caliber executives to cement DDC’s market leading position in the private DNA testing market and position the Company for continued success.”
Robert W. Baird & Co served as the financial advisor to DDC and MTS. Hogan Lovells provided legal counsel to DDC and MTS.
DDC is one of the largest DNA testing companies in the world. Founded 20 years ago, DDC offers comprehensive DNA testing services for paternity and other family relationships, forensics, cell line authentication, and ancestry. DDC receives more than 800,000 consumer calls each year, and will perform over 750,000 DNA tests in 2015. DDC’s Dual Process™ ensures all collected DNA samples are independently tested twice producing legal results of unmatched quality and reliability. DDC is recognized through a number of accreditations nationally and internationally including those performed by the American Association of Blood Banks (AABB), The Ministry of Justice, and the College of American Pathologists (CAP). DDC is also accredited by ACLASS to meet the standards of ISO 17025 and the American Society of Crime Laboratory Directors / Laboratory Accreditation Board-International and follows the DNA Advisory Board (DAB) guidelines, which attests to DDC’s superior forensic testing service. For more information, please visit www.dnacenter.com.
MTS Health Investors, LLC, located in New York, is a healthcare private equity firm that makes investments in operating companies within the healthcare industry. MTS focuses on companies that deliver greater value for every dollar spent in healthcare. Industry sectors in which MTS invests include: providers of outsourced solutions to the healthcare industry; providers of direct medical services to patients in an institutional, ambulatory, or home setting; providers of managed care and other healthcare insurance services; distributors of medical products; and manufacturers of low-technology medical devices and supplies.
For further information, please visit www.mtshealthinvestors.com.